Hot Investor Mandate: Corporate Finance Firm Invests in Clinical-Stage Therapeutics and Diagnostics

21 Mar

A Corporate Finance firm focused on venture and private equity investments supports SMEs across Europe with attention to Austria. The company has built a track record of creating significant value as investors by developing deep industry expertise in sectors including renewable energy, high-tech and bio-tech.

The firm is interested in companies in the therapeutics and diagnostics space in particular and is open to considering medical device companies as well. The firm is open to any indication and sub-sector but requires that the firm’s asset be ready to enter a Phase I study in order to be considered.

The firm is looking for private companies with exceptional management teams in place. The firm often looks to take a board seat and provide a lot more than just financial aid to companies they invest in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Raises New Fund For Platform Technologies

21 Mar

A venture capital firm based Switzerland raised a new fund in 2019.  The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 5 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe, with a core focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, medtech etc.. The firm focuses on companies developing biotech platforms, research tools and digital health startups. The firm will not invest in pure drug development companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, antibody development platforms and a technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Austria Firm Invests Opportunistically In Life Science Deals

21 Mar

An investment firm based in Austria manages a total of EUR 50 million in capital, and invests in seed and early stage opportunities in Austria. The firm initially invests up to EUR 1 million, with further capital reserved for potential follow-on rounds.

The firm will consider investing in any area of life science technology, including biotech, medical devices, diagnostics, and also agtech and environmental biotech. The firm is open to investing in early-stage companies that have not yet commenced human clinical trials; however, the firm will only invest in companies that have a working prototype or animal data for their product. While the firm will consider any technology or indication area, the firm generally prefers not to invest in health apps, or in fields such as oncology that incur high costs for clinical development.

The firm focuses on investing in their local area close to Vienna. The firm is open to being a lead investor but prefers not to be the sole investor in a round; the firm syndicates with other VCs and other sources of capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: